Featured Products
Our Promise to You
Guaranteed product quality, expert customer support
ONLINE INQUIRY
OCI-LY-19
Cat.No.: CSC-C9229W
Source: B cell lymphoma
Morphology: single round cells
- Specification
- Background
- Scientific Data
- Q & A
- Customer Review
The OCI-LY-19 cell line is a valuable model system for studying diffuse large B-cell lymphoma (DLBCL), a common and aggressive subtype of non-Hodgkin lymphoma (NHL). This cell line was established in 1987 from the bone marrow of a 27-year-old woman with stage 4B DLBCL, at the time of relapse.
The availability of the OCI-LY-19 cell line has provided researchers with a valuable tool to investigate the molecular and cellular characteristics of DLBCL. As a model system derived from a patient at relapse, the OCI-LY-19 cells offer insights into the pathways and genetic alterations that may contribute to disease progression and treatment resistance. Researchers have utilized this cell line to elucidate key signaling cascades, identify potential therapeutic targets, and explore novel treatment approaches for DLBCL.
Combinations With BET Inhibitors and LRRK2 as a Novel Putative Target in Lymphoma
Inhibitors of the Bromo- and Extra-Terminal domain (BET) family proteins have strong preclinical antitumor activity in multiple tumor models, including lymphomas. The combination between LRRK2-IN-1 and birabresib was also evaluated using the efficacy and potency parameter (CIT) according to the MuSyC algorithm, showing additivity in efficacy and between additivity and synergism in the potency parameter in all the cell lines tested.
To uncover the importance of LRRK2 protein in the growth of GCB DLBCL cell lines (OCI-LY-19 and WSU-DLCL2), a silencing of LRRK2 by siRNAs was performed. LRRK2 silencing affected the cell growth causing a reduction in cell growth after 48 h of silencing (Fig. 1A-C). Total and phosphorylated GSK3β and AKT proteins were analyzed, due to their possible association with the function of LRRK2. LRRK2 silencing led to a downregulation of p-AKT (S473) and p-GSK3β (S9) levels (Fig. 2). The effect on cell proliferation after LRRK2 silencing was increased when LRRK2 siRNAs were combined with the BET inhibitor birabresib. There was a beneficial effect on the proliferation between LRRK2 silencing and birabresib treatment in OCI-LY-19 (48 h) (Fig. 2A). LRRK2 silencing was performed with four individual siRNAs present in the pool. A consistent reduction of proliferation compared to control siRNAs was increased when combined with birabresib (Fig. 2D).
Fig. 1 LRRK2 is important for lymphoma cell lines (OCI-LY-19 and WSU-DLCL2). (Spriano F, et al., 2022)
Fig. 2 Birabresib improves the LRRK2 silencing effect in OCI-LY-19. (Spriano F, et al., 2022)
Critical parameters include authentic cell lines, absence of contamination, and consistent cell behavior, which contribute to the reproducibility of experiments.
OCI-LY-19 cells are characterized as a B-cell non-Hodgkin lymphoma cell line. They represent a specific subtype of the disease, namely DLCL, and were obtained from a patient's bone marrow at the relapse stage.
OCI-LY-19 cells are valuable for research and drug development related to B-cell non-Hodgkin lymphoma, particularly the DLCL subtype. These cells serve as an important model system for studying the biology and response of B-NHL to various treatments and experimental therapies.
OCI-LY-19 cells are used in a wide range of scientific experiments to investigate the behavior, characteristics, and response of B-NHL cells to different stimuli, compounds, and treatments. These experiments play a crucial role in advancing our knowledge of B-cell non-Hodgkin lymphoma and developing potential therapeutic strategies.
Ask a Question
Average Rating: 4.7 | 3 Scientist has reviewed this product
Accelerating the tumor research
This tumor cell product has accelerated my research substantially. With the cells readily available, I can bypass the time-consuming process of establishing and expanding my cell lines.
09 Jan 2023
Ease of use
After sales services
Value for money
In excellent condition
The cells arrive in excellent condition and maintain their characteristics consistently, which has been crucial for the success of my projects.
13 Oct 2023
Ease of use
After sales services
Value for money
Responsive and helpful team
The team at Creative Bioarray has been extremely responsive and helpful, providing detailed technical support and ensuring a smooth ordering process.
12 Mar 2024
Ease of use
After sales services
Value for money
Write your own review
- You May Also Need
Description: Established from the primary lesion resected from a 76-year-old woman with bulky, moderately differentiated squamous cell carcinoma of the vulva in 1984; cells were reported to express an elevated number of high affinity EGF receptors, to carry gene amplification at 11q13 and to be tumorigenic in nude mice
Description: Established from the solid tumor of a 52-year-old Caucasian man with advanced stage malignant bile duct carcinoma (patient had not received any chemotherapy prior to cell explantation) in 1984 and three consecutive passages in female nu/nu mice (NMRI); primary tumor histology: large cell adenocarcinoma of low differentiation, metastasizing (ascites in patient); human character of cell line confirmed by karyotype in passage #34 of in vitro culture (1986)
Description: Subclone of ACH1P which was established by fusion of the JEG-3-derived HGPRT-defective mutant cell line AC1-1 with primary male trophoblast cells isolated from term human chorion laeve; described as possessing both, a distinct karyotype and a distinct expression pattern of tumor-related genes
Description: One of five phenotypically and cytogenetically distinct subclones of a hybrid (ACH1P) formed by fusing an HGPRT-defective mutant (AC1-1) of JEG-3 human choriocarcinoma with primary human trophoblast (chorion laeve) cells
Description: Established by somatic hybridization of primary male trophoblast cells and the HGPRT-defective choriocarcinoma cell line AC1-1 which was originally derived from cell line JEG-3
Description: NTERA-2 was cloned from cell line TERA-2 which was derived from a metastatic teratocarcinoma of a 22-year-old Caucasian male; cell line also known as NT-2
